Covered recipient · General Payments record
REBECCA AREND
Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$26,734.73
68 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $13,625.00 | 5 |
| Travel and Lodging | $6,094.34 | 25 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,100.00 | 2 |
| Food and Beverage | $1,853.34 | 34 |
| Education | $62.05 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $10,169.63 | 14 |
| TESARO, Inc. | $8,440.75 | 29 |
| PFIZER INC. | $5,245.13 | 3 |
| Clovis Oncology, Inc. | $2,556.30 | 14 |
| Exelixis Inc. | $110.06 | 1 |
| AstraZeneca UK Limited | $80.00 | 1 |
| AstraZeneca Pharmaceuticals LP | $71.07 | 3 |
| Foundation Medicine, Inc. | $37.31 | 1 |
| Puma Biotechnology, Inc. | $13.00 | 1 |
| EISAI INC. | $11.48 | 1 |
Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
REBECCA AREND
NPI 1437309283 · CMS profile ID 1303605
Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology
BIRMINGHAM, AL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1437309283?year=2019&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- REBECCA AREND, NPI 1437309283, CMS profile ID 1303605. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437309283?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). REBECCA AREND, NPI 1437309283, CMS profile ID 1303605. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437309283?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- REBECCA AREND, NPI 1437309283, CMS profile ID 1303605, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1437309283?year=2019&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
68 matching records · $26,734.73 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–68 of 68.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| TESARO, Inc. | $91.00 | 03/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675554049 | CMS |
| Clovis Oncology, Inc. | $24.33 | 03/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688680251 | CMS |
| Clovis Oncology, Inc. | $14.66 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688680253 | CMS |
| Clovis Oncology, Inc. | $15.44 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688680255 | CMS |
| Clovis Oncology, Inc. | $59.87 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688680257 | CMS |
| Clovis Oncology, Inc. | $1,500.00 | 03/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688680259 | CMS |
| Clovis Oncology, Inc. | $337.87 | 03/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688680261 | CMS |
| TESARO, Inc. | $61.03 | 02/08/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675554047 | CMS |
| TESARO, Inc. | $1,100.00 | 01/31/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675554045 | CMS |
| TESARO, Inc. | $2,200.00 | 01/26/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675554029 | CMS |
| TESARO, Inc. | $462.60 | 01/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675554031 | CMS |
| TESARO, Inc. | $209.80 | 01/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675554033 | CMS |
| TESARO, Inc. | $71.97 | 01/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675554035 | CMS |
| TESARO, Inc. | $11.40 | 01/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675554037 | CMS |
| TESARO, Inc. | $40.80 | 01/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675554039 | CMS |
| TESARO, Inc. | $29.71 | 01/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675554041 | CMS |
| TESARO, Inc. | $57.27 | 01/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675554043 | CMS |
| PFIZER INC. | $145.13 | 01/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671924923 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,359.19 | 4 |
| PY2025 | Principal investigator | $3,548,394.96 | 59 |
| PY2024 | Recipient | $362.01 | 2 |
| PY2024 | Principal investigator | $3,189,393.96 | 66 |
| PY2023 | Principal investigator | $1,434,025.66 | 39 |
| PY2022 | Principal investigator | $464,139.51 | 73 |
| PY2021 | Principal investigator | $1,218,353.84 | 337 |
| PY2020 | Principal investigator | $37,993.92 | 48 |
| PY2019 | Recipient | $586.06 | 4 |
| PY2019 | Principal investigator | $32,094.20 | 7 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
63 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $250,789.76 | 12/31/2025 | Covered Recipient Teaching Hospital University Of Alabama Hospital | STUDY NAME#A Phase II Study in Newly Diagnosed Stage III,IV Epithelial Ovarian Cancer Evaluating Carbo,Taxol,Pembro in patients receiving Neoadjuvant Chemotherapy NACT followed by Olaparib,Pembro Maintenance | No dispute reported | 06/30/2026 | 1232931808 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,935.88 | 12/19/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer | No dispute reported | 06/30/2026 | 1184139165 |
| Principal investigator 1 | ABBVIE INC. | $406,941.00 | 12/18/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive | No dispute reported | 06/30/2026 | 1202427523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,539.95 | 12/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer | No dispute reported | 06/30/2026 | 1184139163 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,250.00 | 11/25/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer | No dispute reported | 06/30/2026 | 1184139157 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27,300.00 | 11/25/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer | No dispute reported | 06/30/2026 | 1184139159 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $16,190.00 | 11/25/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer | No dispute reported | 06/30/2026 | 1184139161 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $16,551.60 | 11/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139155 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 11/20/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | No dispute reported | 06/30/2026 | 1202427494 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 11/20/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139153 |
| Principal investigator 1 | ABBVIE INC. | $46,540.00 | 11/17/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | No dispute reported | 06/30/2026 | 1202427471 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $59,583.00 | 11/14/2025 | Non-covered Recipient Entity UNIVERSITY OF ALABAMA AT BIRMINGHAM | A PHASE IB/II SINGLE ARM STUDY OF CABOZANTINIB PLUS DOSTARLIMAB IN WOM | No dispute reported | 06/30/2026 | 1192111627 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $32,640.00 | 11/13/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139147 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27,005.42 | 11/13/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139149 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $30,881.64 | 11/13/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139151 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $400.57 | 11/08/2025 | Covered Recipient Physician | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184115177 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $263.67 | 10/18/2025 | Covered Recipient Physician | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184115175 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,885.67 | 10/14/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139139 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,011.11 | 10/14/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139141 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $63,070.00 | 10/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139131 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $277.33 | 10/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139133 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,200.00 | 10/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139135 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,720.00 | 10/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139137 |
| Principal investigator 1 | ABBVIE INC. | $406,941.00 | 09/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive | No dispute reported | 06/30/2026 | 1202427423 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $21,915.79 | 09/18/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139125 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,370.77 | 09/18/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139127 |
| Principal investigator 1 | ABBVIE INC. | $310,266.00 | 08/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive | No dispute reported | 06/30/2026 | 1202427395 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $166,863.90 | 08/19/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139117 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,517.66 | 08/19/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139119 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $20,069.79 | 08/19/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139121 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,123.66 | 08/19/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139123 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $277.33 | 08/14/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139115 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $24,520.58 | 08/06/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,961.83 | 08/04/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139111 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $315.96 | 08/01/2025 | Covered Recipient Physician | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184115173 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $378.99 | 07/16/2025 | Covered Recipient Physician | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184115171 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,344.79 | 06/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139103 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $576.04 | 06/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139105 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 06/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139107 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $715.00 | 06/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139109 |
| Principal investigator 1 | ABBVIE INC. | $135,647.00 | 06/20/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. | No dispute reported | 06/30/2026 | 1202427337 |
| Principal investigator 1 | ABBVIE INC. | $271,294.00 | 06/17/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. | No dispute reported | 06/30/2026 | 1202427325 |
| Principal investigator 1 | ABBVIE INC. | $67,823.50 | 05/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. | No dispute reported | 06/30/2026 | 1202427289 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $170.00 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139097 |
| Principal investigator 1 | ABBVIE INC. | $203,470.50 | 05/22/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. | No dispute reported | 06/30/2026 | 1202427282 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,487.79 | 05/08/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139093 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $36,041.07 | 05/08/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139095 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 04/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139091 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $277.33 | 04/17/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139085 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $28,092.29 | 04/17/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139087 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $59,583.68 | 04/15/2025 | Non-covered Recipient Entity UNIVERSITY OF ALABAMA AT BIRMINGHAM | A PHASE IB/II SINGLE ARM STUDY OF CABOZANTINIB PLUS DOSTARLIMAB IN WOM | No dispute reported | 06/30/2026 | 1192171884 |
| Principal investigator 1 | ABBVIE INC. | $67,823.50 | 04/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. | No dispute reported | 06/30/2026 | 1202427264 |
| Principal investigator 1 | ABBVIE INC. | $67,823.50 | 04/08/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. | No dispute reported | 06/30/2026 | 1202427257 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $44,546.58 | 03/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139079 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $24,450.68 | 03/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139081 |
| Principal investigator 1 | ABBVIE INC. | $310,266.00 | 03/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A25-401 - Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive | No dispute reported | 06/30/2026 | 1202427227 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,831.63 | 02/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139077 |
| Principal investigator 1 | ABBVIE INC. | $67,823.50 | 02/25/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. | No dispute reported | 06/30/2026 | 1202427207 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,277.86 | 02/20/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139069 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $576.04 | 02/20/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139071 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $277.33 | 02/20/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139073 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,146.89 | 02/20/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139075 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $65,687.79 | 02/06/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF ALABAMA HOSPITAL | A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | No dispute reported | 06/30/2026 | 1184139067 |